Roger Véronique L
Division of Cardiovascular Diseases, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Med Clin North Am. 2007 Jul;91(4):537-52; ix. doi: 10.1016/j.mcna.2007.03.007.
Myocardial infarction is a key component of the burden of cardiovascular disease. The assessment of the incidence and case fatality of myocardial infarction are important determinants of the decline in coronary disease mortality. The change in biomarkers used to diagnose myocardial infarction raises several methodologic, clinical, and public health challenges, which are discussed herein.
心肌梗死是心血管疾病负担的关键组成部分。对心肌梗死发病率和病死率的评估是冠心病死亡率下降的重要决定因素。用于诊断心肌梗死的生物标志物的变化带来了一些方法学、临床和公共卫生方面的挑战,本文将对此进行讨论。